Takara Bio And MolMed S.p.A. Announce That Phase I/II Clinical Trial Of HSV-TK Gene Therapy Delivers Positive Results

Tokyo (JCN) Dec 15, 2005 - Takara Bio announced on December 13 that its Italian research partner MolMed has presented the results of phase I and II clinical trials of HSV-TK gene therapy, which targets hematopoietic malignancies, at the 47th Annual Meeting of the American Society of Hematology held in Atlanta.

MORE ON THIS TOPIC